• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconPharmaceutical Industry

Pharmaceutical Industry

Page 18 of 100
U.S. drug price negotiations are underway. Here’s what that will mean for you—eventually
Finance
U.S. drug price negotiations are underway. Here’s what that will mean for you—eventually
By Chris MorrisFebruary 2, 2024
The last time there was this much hype over a new drug was for Viagra, which was approved in 1998. Yet hurdles remain, when it comes to the ability of patients to access weight loss and anti-diabetes injectables like Zepbound and Wegovy: These drugs cost a lot, insurance coverage is spotty, and patients may need to take them indefinitely to avoid regaining weight.
Health
Weight-loss injectables like Zepbound are making as big of a splash as Viagra, if not bigger. What you need to know about the ‘miracle drugs’
By Emma Court, Madison Muller and BloombergJanuary 31, 2024
‘We are using all the tools we have’: Lina Khan’s FTC takes aim at Big Pharma’s ‘patent thickets’, arguing they keep old drugs too pricey
Politics
‘We are using all the tools we have’: Lina Khan’s FTC takes aim at Big Pharma’s ‘patent thickets’, arguing they keep old drugs too pricey
By Elisabeth Rosenthal and KFF Health NewsJanuary 31, 2024
Big Pharma's favorite lab monkey, the long-tailed macaque.
Magazine
Big Pharma’s great lab monkey shortage: A crackdown on smuggling is causing chaos in America’s vital drug development pipeline
By Erika FryJanuary 27, 2024
A long-tailed macaque being held by lab employees.
Features
Why Big Pharma can’t quit the lab monkey business
By Erika FryJanuary 27, 2024
a laboratory monkey sitting in its cage in the breeding centre for cynomolgus macaques (longtail macaques) at the National Primate Research Center of Thailand
Features
What losing vision in one eye helped me understand about animal research
By Erika FryJanuary 27, 2024
The Food and Drug Administration authorized importation of penicillin G benzathine made by a French company, Laboratoires Delbert. Pfizer’s Bicillin L-A, the only version of the drug available in the U.S., has been in short supply since April.
Health
FDA allows imports of French syphilis drug alternate during US penicillin shortage
By Ike Swetlitz and BloombergJanuary 10, 2024
person standing in front of a countdown clock in front of Paris's Eiffel Tower
Lifestyle
Gen X drugmaker is coughing up millions for Paris Olympics sponsorship to show Gen Z and millennials it’s a cool place to work
By Prarthana PrakashJanuary 10, 2024
Alphabet’s Isomorphic Labs to collaborate with Novartis, Lilly on AI-driven drug discovery
Health
Alphabet’s Isomorphic Labs to collaborate with Novartis, Lilly on AI-driven drug discovery
By Susanne Barton and BloombergJanuary 8, 2024
Boston Scientific headquarters as pictured on Jan. 19, 2007. The company acquired device-maker Axonics Inc. for $2.7 billion on Monday.
Health
J&J, Merck, Boston Scientific go on $6.4B buying spree
By Fiona Rutherford and BloombergJanuary 8, 2024
Eli Lilly and Company says its popular drugs Mounjaro and Zepbound, also known as GLP-1s, are not meant for those without obesity or type 2 diabetes.
Health
Eli Lilly cracks down on the use of weight loss drugs Mounjaro and Zepbound for ‘cosmetic’ reasons instead of for diabetes and obesity
By Alexa MikhailJanuary 4, 2024
Ozempic, Wegovy demand so strong Europe’s most valuable listed company plans ‘mega manufacturing facility’
Health
Ozempic, Wegovy demand so strong Europe’s most valuable listed company plans ‘mega manufacturing facility’
By Ellie Harmsworth and BloombergDecember 24, 2023
Pharma will pay rebates in 2024 on 48 drugs whose prices rose more than inflation this year: ‘Let’s call this for what it is—it simply is a rip off’
Health
Pharma will pay rebates in 2024 on 48 drugs whose prices rose more than inflation this year: ‘Let’s call this for what it is—it simply is a rip off’
By Amanda Seitz and The Associated PressDecember 15, 2023
Why business should pay attention to the Supreme Court’s latest mifepristone case
Newsletters
Why business should pay attention to the Supreme Court’s latest mifepristone case
By Emma Hinchliffe and Joey AbramsDecember 14, 2023
Climate change is unleashing a tsunami of infectious diseases–and we have fewer and fewer drugs that can treat them
Commentary
Climate change is unleashing a tsunami of infectious diseases–and we have fewer and fewer drugs that can treat them
By Jayasree K. IyerDecember 11, 2023
1...
  • 16
  • 17
  • 18
  • 19
  • 20
...100
Most Popular
Success
IBM’s CEO disagrees with JPMorgan CEO Jamie Dimon’s disdain for texting in meetings: ‘Telling people they can't use their technology would be weird’placeholder alt text
By Preston ForeAugust 29, 2026
Success
Richard Branson double-booked his own job interview. The candidate stuck in traffic with him for 2.5 hours is now Virgin's CEOplaceholder alt text
By Preston ForeAugust 29, 2026
Big Tech
Tech billionaires and executives like Evan Spiegel and Peter Thiel are publicly shielding their children from the products that made them richplaceholder alt text
By Marco Quiroz-GutierrezAugust 29, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

    © 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
    FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.